Neurogene Inc. reported late Tuesday that it has commenced a public offering of its common stock and, for certain investors, pre-funded warrants exercisable into common stock. The news coincided with a roughly 3% drop in the company’s shares in after-hours trading that followed the announcement.
Under terms outlined by the company, the underwriters will also be granted a 30-day option to purchase additional shares at the public offering price, less any underwriting discounts and commissions. The exact size, pricing and timing of the offering were not disclosed, and the company emphasized that the transaction remains subject to prevailing market and other conditions.
Neurogene said it plans to apply the net proceeds from the offering, combined with its existing cash, cash equivalents and marketable securities, toward the continuing clinical development of NGN-401, pre-commercial activities for NGN-401, and for working capital and other general corporate purposes. NGN-401 is the company’s gene therapy program being advanced for Rett syndrome.
The company reiterated that there is no assurance as to whether or when the proposed public offering will be completed, or what the ultimate size or terms will be; market conditions could affect execution or timing. The proposed offering is therefore conditional and not guaranteed.
Leerink Partners, Stifel, Guggenheim Securities, LifeSci Capital and William Blair are named as joint bookrunning managers for the proposed offering. Neurogene is a clinical-stage biotechnology company focused on developing genetic medicines for neurological diseases and is advancing NGN-401 as a candidate for Rett syndrome.
Context and implications
The company’s decision to raise capital through a public offering is presented as a means to support program advancement and corporate liquidity. The immediate market reaction was modest, with a single-session, after-hours decline of about 3% noted in the trading that followed the disclosure.
Beyond the transaction mechanics, Neurogene’s statement contains explicit caveats that the offering depends on market and other conditions and that the final terms are not assured. These limitations frame the near-term uncertainty for investors until the offering is completed or further details are disclosed.